Minoxidil alone may not stop hair loss. Finasteride is recommended for androgenic alopecia, as minoxidil doesn't prevent DHT from miniaturizinghairfollicles.
HairClone aims to rejuvenate miniaturizinghairfollicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hairfollicles, but full regenerative treatments will take many years to develop.
Hair loss impacts mental health, with treatments like Minoxidil, finasteride, and stem cell transplants discussed. There is hope for future breakthroughs, but current treatments are limited, and awareness is lacking.
A permanent hair loss solution could involve reprogramming hairfollicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.
PP405 shows promise for reactivating hairfollicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.
The conversation discusses difficulty in distinguishing between new hair growth and thinning hair at the temples after using microneedling and a rosemary peppermint topical for four weeks. The advice given is to wait a few months to see if the hairs grow out to determine their nature.
HairClone is developing cell replacement treatments to rejuvenate and generate hairfollicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.
The conversation discusses the confusion over low testosterone potentially causing hair loss, with users sharing personal experiences and knowledge about hair loss treatments like Finasteride. Some users suggest that hairfollicle sensitivity to DHT, not testosterone levels, is the key factor in balding, and others discuss the side effects of hair loss medications.
DHT is not the only cause of male pattern hair loss; genetic sensitivity, inflammation, and fibrosis also contribute. GHK-Cu, a copper peptide, is being explored as an alternative treatment to finasteride and minoxidil, showing potential in improving follicle health.
Pelage is developing a topical hairfollicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
PP405 is not a cure for hair loss but may reactivate dormant hairfollicles, similar to minoxidil. It is unlikely to help with miniaturized or vellus hairs and is still in trial phases, with availability expected around 2030.
PP405 is a new hair loss treatment targeting dormant hairfollicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
UCLA's PP405 shows promise in reactivating dormant hairfollicles for hair loss treatment but is still in clinical trials. Minoxidil and finasteride remain common treatments until PP405 becomes available.
Finasteride prevents further hair loss by blocking DHT, while minoxidil stimulates hair growth by prolonging the active phase of hairfollicles. Stopping minoxidil can lead to loss of regrown hair because finasteride does not address the same growth mechanism.
Hair loss treatments like Minoxidil, finasteride, and stem cell therapies exist, but a complete cure is hindered by genetic complexity and market dynamics. Cloning hairfollicles is considered a potential solution, but it's currently not feasible.
Diffuse thinners often experience more hair regrowth with DHT blockers like finasteride, possibly due to less DHT sensitivity and the presence of miniaturized, not completely bald, follicles. However, regrowth varies widely among individuals, influenced by factors like genetics, the stage of hair loss, and treatment methods such as minoxidil, microneedling, and dermarolling.
A satirical post where someone claims to have developed a radioactive isotope scalp serum using Polonium-210 that outperforms Minoxidil and finasteride for hair regrowth. The serum reportedly stimulates DNA repair in hairfollicles, leading to significant hair density increase, but the post is met with skepticism and concerns about safety.
Resveratrol and fisetin, found in red wine and strawberries, may promote hair growth by affecting hairfollicle cells. Users discuss various treatments, including natural remedies like saw palmetto and topical applications, with mixed opinions on their effectiveness compared to pharmaceuticals like finasteride.
A person experienced hair loss after switching from finasteride to dutasteride and returned to finasteride, adding oral minoxidil. Dutasteride may increase scalp testosterone, worsening hair loss for some individuals.
A user's progress with treating their hair loss, including using finasteride, minoxidil, retinoic acid, dermapenning twice weekly and ket 2% shampoo two to three times per week. Other users offered advice such as not derma penning too often or shaving the area bald for a couple of months.
The conversation discusses a hair loss treatment regimen involving dutasteride, pyrilutamide, oral minoxidil, and microneedling, with the aim of suppressing DHT and stimulating hair growth. Users debate the effectiveness and potential side effects of these treatments, noting that individual results may vary and that no treatment is foolproof.
Feeding bacteria-free mice with Lactobacillus murinus worsened hair loss, but a regular diet with biotin stopped it. The conversation suggests gut bacteria and diet may influence hair loss, with some skepticism and discussion about other factors like DHT and genetics.
Hair loss may be linked to DHT, which can both suppress and increase inflammation, potentially as a defense mechanism. Treatments like Minoxidil, Finasteride, and RU58841 are discussed, but the exact cause of hair loss remains unclear.
Discontinuing Minoxidil typically returns hair to baseline, but some believe it may go below baseline temporarily. Continuing finasteride or dutasteride is recommended.
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
After a hair transplant, the user noticed unexpected new hair growth without using medications or vitamins. Many advised starting treatments like minoxidil and finasteride to maintain the results and prevent future hair loss.
A 28-year-old is considering using topical 0.3% finasteride and 6% minoxidil spray to prevent further hairline recession. They are unsure if this treatment is too drastic for their current level of hair loss and seek advice on application methods.
Treating hair loss with finasteride, dutasteride and minoxidil, as well as micro-needling, potentially using research chemicals such as Pyril and Senzu Beans.